3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Astrocytoma
8
Glioblastoma
5
Neuroectodermal Tumors, Primitive
3
Recurrence
2
Oligodendroglioma
2
Neurocytoma
2
Lymphoma, Non-Hodgkin
2
Glioma
2
Brain Neoplasms
2
Rhabdoid Tumor
1
Pancreatic Neoplasms
1
Neoplasms, Unknown Primary
1
Multiple Myeloma
1
Mesothelioma, Malignant
1
Meningioma
1
Melanoma
1
Lung Neoplasms
1
Gliosarcoma
1
Ganglioglioma
1
Esophageal Neoplasms
1
Ependymoma
1
Craniopharyngioma
1
Carcinoma, Non-Small-Cell Lung
1
Adrenocortical Carcinoma
1
Adenocarcinoma Of Esophagus
1
Interventions
Sunitinib
19
Everolimus
17
Bevacizumab
13
aldesleukin
11
Sorafenib
11
Interleukin-2
10
Cyclophosphamide
10
Axitinib
10
Nivolumab
9
fludarabine phosphate
7
fludarabine
7
pembrolizumab
5
Gemcitabine
5
temsirolimus
4
pazopanib
4
Ipilimumab
4
peginterferon alfa-2b
3
durvalumab
3
cabozantinib
3
Radiosurgery
3
Interferon-alpha
3
Granulocyte-Macrophage Colony-Stimulating Factor
3
Filgrastim
3
Erlotinib Hydrochloride
3
Cryosurgery
3
vandetanib
2
spartalizumab
2
perflutren
2
ixabepilone
2
chiron
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Kidney Neoplasms
×
antineoplaston AS 2-1
×
Clear all
No trials found.